[1] Gurusamy KS, Davidson BR.Gallstones[J]. BMJ,2014,348:g2669. [2] 中华外科学会胆道外科学组. 我国胆石病十年来的变迁[J]. 中华外科杂志,1995,33(11):652-658. [3] 陈希纲, 刘家奇. 胆石病临床流行病学调查——附8585例分析[J]. 中华普通外科杂志,2002,17(2):99-101. [4] 蒋兆彦, 胡海, 韩天权, 等. 胆固醇的肠肝循环:肝脏和小肠在胆石形成中的作用[J]. 外科理论与实践,2017,22(3):191-194. [5] Abraham S, Rivero HG, Erlikh IV, et al.Surgical and nonsurgical management of gallstones[J]. Am Fam Physician,2014,89(10):795-802. [6] 蒋兆彦, 吴健, 韩天权, 等. 胆固醇结石病防治研究的再发展[J]. 外科理论与实践,2015,20(2):108-111. [7] Jiang ZY, Jiang CY, Wang L, et al.Increased NPC1L1 and ACAT2 expression in the jejunal mucosa from Chinese gallstone patients[J]. Biochem Biophys Res Commun,2009,379(1):49-54. [8] Jiang ZY, Parini P, Eggertsen G, et al.Increased expression of LXR alpha, ABCG5, ABCG8, and SR-BI in the liver from normolipidemic, nonobese Chinese gallstone patients[J]. J Lipid Res,2008,49(2):464-472. [9] Altmann SW, Davis HR, Zhu L, et al.Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption[J]. Science,2004,303(5661):1201-1204. [10] Wang HH, Portincasa P, de Bari O, et al. Prevention of cholesterol gallstones by inhibiting hepatic biosynthesis and intestinal absorption of cholesterol[J]. Eur J Clin Invest,2013,43(4):413-426. [11] Carey MC.Critical tables for calculating the cholesterol saturation of native bile[J]. J Lipid Res,1978,19(8):945-955. [12] Garcia-Calvo M, Lisnock J, Bull HG, et al.The target of ezetimibe is Niemann-Pick C1-like 1 (NPC1L1)[J]. Proc Natl Acad Sci U S A,2005,102(23):8132-8137. [13] Xie C, Zhou ZS, Li N, et al.Ezetimibe blocks the internalization of NPC1L1 and cholesterol in mouse small intestine[J]. J Lipid Res,2012,53(10):2092-2101. [14] Sudhop T, Lütjohann D, Kodal A, et al.Inhibition of intestinal cholesterol absorption by ezetimibe in humans[J]. Circulation,2002,106(15):1943-1948. [15] Reynier MO, Montet JC, Gerolami A, et al.Comparative effects of cholic, chenodeoxycholic, and ursodeoxycholic acids on micellar solubilization and intestinal absorption of cholesterol[J]. J Lipid Res,1981,22(3):467-473. [16] Ge L, Wang J, Qi W, et al.The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1[J]. Cell Metab,2008,7(6):508-519. [17] Zúñiga S, Molina H, Azocar L, et al.Ezetimibe prevents cholesterol gallstone formation in mice[J]. Liver Int,2008, 28(7):935-947. [18] Bari OD, Wang HH, Portincasa P, et al.Ezetimibe prevents the formation of estrogen-induced cholesterol gallstones in mice[J]. Eur J Clin Invest,2014,44(12):1159-1168. [19] Yu L, Hammer RE, Lihawkins J, et al.Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol secretion[J]. Proc Natl Acad Sci U S A,2002,99(25):16237-16242. [20] Yu L, Jia LH, Hammer RE, et al.Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol[J]. J Clin Invest,2002,110(5):671-680. [21] Repa JJ, Berge KE, Pomajzl C, et al.Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta[J]. J Biol Chem,2002,277(21):18793-18800. [22] Brown MS, Goldstein JL.The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor[J]. Cell,1997,89(3):331-340. [23] Fuchs M, Ivandic B, Müller O, et al.Biliary cholesterol hypersecretion in gallstone-susceptible mice is associated with hepatic up-regulation of the high-density lipoprotein receptor SRBI[J]. Hepatology,2001,33(6):1451-1459. [24] Mardones P, Quiñones V, Amigo L, et al.Hepatic cholesterol and bile acid metabolism and intestinal cholesterol absorption in scavenger receptor class B type I-deficient mice[J]. J Lipid Res,2001,42(2):170-180. [25] Kozarsky KF, Donahee MH, Rigotti A, et al.Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels[J]. Nature,1997,387(6631):414-417. [26] Kan HP, Guo WB, Tan YF, et al. Statin use and risk of gallstone disease: A meta-analysis[J]. Hepatol Res,2014-10-09 [Epub ahead of print]. [27] Suuronen S, Niskanen L, Paajanen P, et al.Declining cholecystectomy rate during the era of statin use in Finland: a population-based cohort study between 1995 and 2009[J]. Scand J Surg,2013,102(3):158-163. [28] Bodmer M, Brauchli YB, Krähenbühl S, et al.Statin use and risk of gallstone disease followed by cholecystectomy[J]. JAMA,2009,302(18):2001-2007. [29] 蒋兆彦, 韩天权, 张圣道. 从胆石成因研究谈胆石病预防的新策略[J]. 中华肝胆外科杂志,2011,17(9):697-700. |